The clot-busting drug tissue plasminogen activator (tPA) is currently the only FDA-approved therapy for acute stroke. However, increasing evidence suggests that tPA can also contribute to excitotoxic ...
The usual cause of stroke is an acute interruption of cerebral blood flow that compromises tissue energy stores. The major consequence of this metabolic deprivation is dysfunction of excitatory ...
Please provide your email address to receive an email when new articles are posted on . NEW YORK — Vitrectomy using balanced saline solution without tissue plasminogen activator is effective for ...
August 19, 2009 (UPDATED August 24, 2009) — In May, the American Heart Association (AHA)/American Stroke Association (ASA) gave the green light to the use of tissue plasminogen activator (tPA) to ...
A new analysis supports the use of intravenous (IV) tenecteplase over IV alteplase (tissue plasminogen activator) for treatment of acute ischemic stroke. The analysis found that patients with ischemic ...
A new study published online in the Journal of Trauma and Acute Care Surgery in March 2020 reports that the anticoagulation drug tPA could be a potential aid in managing respiratory failure in ...
Clinical Relevance of Invasion Factors Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1 for Individualized Therapy Decisions in Primary Breast Cancer Is Greatest When ...
Measurements of Proteases or Protease System Components in Blood to Enhance Prediction of Disease Risk or Outcome in Possible Cancer To assess whether preoperative plasma levels of urokinase-type ...
SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights, the global tissue plasminogen activator market is estimated to be valued at US$ 2,455.4 million in 2020 and is expected to exhibit a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback